Advertisement
Australia markets closed

  • ALL ORDS

    7,817.40
    -81.50 (-1.03%)
     

  • ASX 200

    7,567.30
    -74.80 (-0.98%)
     

  • AUD/USD

    0.6421
    -0.0004 (-0.07%)
     

  • OIL

    83.24
    +0.51 (+0.62%)
     

  • GOLD

    2,406.70
    +8.70 (+0.36%)
     

  • Bitcoin AUD

    100,376.87
    +1,734.86 (+1.76%)
     

  • CMC Crypto 200

    1,334.09
    +21.46 (+1.57%)
     

  • AUD/EUR

    0.6023
    -0.0008 (-0.13%)
     

  • AUD/NZD

    1.0893
    +0.0018 (+0.17%)
     

  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     

  • NASDAQ

    17,037.65
    -356.67 (-2.05%)
     

  • FTSE

    7,895.85
    +18.80 (+0.24%)
     

  • Dow Jones

    37,986.40
    +211.02 (+0.56%)
     

  • DAX

    17,737.36
    -100.04 (-0.56%)
     

  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

Inspire Medical Systems, Inc. to Present at the RBC Capital Markets 2023 Global Healthcare Conference

Inspire Medical Systems
·1-min read
Inspire Medical Systems
Inspire Medical Systems

MINNEAPOLIS, May 03, 2023 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the RBC Capital Markets 2023 Global Healthcare Conference on Tuesday, May 16, 2023.

Inspire is scheduled to present at 1:35 p.m. Eastern Time. The presentation will be accessible via a live webcast here.

A webcast replay of the presentation will be available for two weeks following the presentation in the Event Archive section of Inspire’s Investor website at https://investors.inspiresleep.com.

ADVERTISEMENT

About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.

For additional information about Inspire, please visit www.inspiresleep.com.

Investor and Media Contact
Ezgi Yagci
Vice President, Investor Relations
ezgiyagci@inspiresleep.com
617-549-2443